This section of the website provides information on funds which are registered for marketing to private or professional investors for the selected country.

The funds presented in this section of the website may not be available to persons subject to another jurisdiction by virtue of their nationality, their place of residence, or any other reason. See the disclaimer (read our Terms of Use).

The user is solely responsible for correctly indicating his/her country and categorization before accessing sections of this website with information relating to funds, in accordance with the Terms of Use and the Privacy Policy.

The website is provided for information purposes only. No part of this website constitutes a solicitation to invest in funds managed by ECP or in any other investment product. See the Terms of Use.

Prospective investors should be aware that past performance is no indication of future returns.
Prospective investors should refer to the prospectus and Key Investor Information Document (KIID) in particular to the sections dedicated to specific risks of the relevant investment strategies before taking any action and should generally seek professional and independent advice before making an investment decision. See the Terms of Use.

European Capital Partners (Luxembourg) S.A. accepts no liability for any loss or damage resulting from the use of this website, in accordance with the Terms of Use.

I hereby declare that:

I am aware of the rules applicable to me and I wish to access this part of the website containing fund information and data.
I am familiar with and accept in full this disclaimer as well as the Terms of Use and the Privacy Policy.

An example of undervalued earning power

Mar 24, 2023

After a series of disappointments, the fundamentals and operating environment for the French pharmaceutical group Sanofi are improving. Following positive litigation news in the Zantac class action late last year, yesterday the company could indeed present rather stunning late stage clinical results for its blockbuster drug Dupixent when it is used for the treatment of the smoker’s lung.

We believe the earning power of the company is improving at a time it trades at a valuation discount to the pharmaceutical sector and the market in general. In terms of price / earnings it is valued at 10.5 times next year’s earnings and the company scores well on both quality and value scores. This defensive large cap remains a core holding in our European value portfolio and deserves in our opinion a re-rating (all usual disclaimers apply).

Return to overview

Please select your investor profile

Please select your country of residence

Warning

An example of undervalued earning power

Mar 24, 2023